The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 29, 2018
Filed:
Jun. 28, 2012
Hai Yan, Chapel Hill, NC (US);
Darell Bigner, Mebane, NC (US);
Bert Vogelstein, Baltimore, MD (US);
Kenneth W. Kinzler, Baltimore, MD (US);
Alan Meeker, Pikesville, MD (US);
Ralph Hruban, Baltimore, MD (US);
Nickolas Papadopoulos, Towson, MD (US);
Luis Diaz, Ellicott City, MD (US);
Yuchen Jiao, Baltimore, MD (US);
Hai Yan, Chapel Hill, NC (US);
Darell Bigner, Mebane, NC (US);
Bert Vogelstein, Baltimore, MD (US);
Kenneth W. Kinzler, Baltimore, MD (US);
Alan Meeker, Pikesville, MD (US);
Ralph Hruban, Baltimore, MD (US);
Nickolas Papadopoulos, Towson, MD (US);
Luis Diaz, Ellicott City, MD (US);
Yuchen Jiao, Baltimore, MD (US);
Duke University, Durham, NC (US);
The Johns Hopkins University, Baltimore, MD (US);
Abstract
We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.